The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

BMJ Open Respir Res. 2020 Dec;7(1):e000741. doi: 10.1136/bmjresp-2020-000741.

Abstract

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted in a significantly greater reduction in lung hyperinflation versus F/S (FRC plethysmography absolute change from baseline: F/S: -0.329 L, T/O: -0.581 L).

Keywords: COPD pharmacology; inhaler devices; respiratory measurement.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Benzoxazines
  • Bronchodilator Agents* / therapeutic use
  • Cross-Over Studies
  • Fluticasone-Salmeterol Drug Combination / therapeutic use
  • Humans
  • Lung
  • Multicenter Studies as Topic
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Randomized Controlled Trials as Topic
  • Tiotropium Bromide / therapeutic use

Substances

  • Benzoxazines
  • Bronchodilator Agents
  • Fluticasone-Salmeterol Drug Combination
  • olodaterol
  • Tiotropium Bromide